NOVO NORDISK PHARMACEUTICALS A/S: Financial statements 2020
CVR: 24257924
Source: annual report 2020, Danish Business Authority
01/01/2020 – 31/12/2020
NOVO NORDISK PHARMACEUTICALS A/S (CVR 24257924) has filed annual accounts for 2020. In 2020, the company reported a net result of DKK -2,368,000 compared with DKK 3,722,000 the year before. Equity in the 2020 report amounted to DKK 2,849,704,000. The solvency ratio was 96.3%.
- Profit/Loss
- DKK -2,368,000
- Equity
- DKK 2,849,704,000
- Total Assets
- DKK 2,958,624,000
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2020 | - | - | -2.4M | 2.8B | - |
| 2019 | - | - | 3.7M | 15.6M | - |
| 2018 | - | - | -2M | 11.8M | - |
| 2017 | - | - | -2.3M | 13.8M | - |
| 2016 | - | - | 1.7M | 16.1M | - |
Official annual report
How creditworthy is NOVO NORDISK PHARMACEUTICALS A/S?
See the CDS score and get a full credit report with recommended credit limit and payment terms.
Read about the CDS scoreEvents in 2020
As of December 15, 2020, Linette Tangsgaard Nielsen has joined the board of directors of NOVO NORDISK PHARMACEUTICALS A/S.
As of December 15, 2020, Lene Moth Bang has left the board of directors of NOVO NORDISK PHARMACEUTICALS A/S.
NOVO NORDISK PHARMACEUTICALS A/S has published its annual report for 2019. The net result was DKK 3,722,000.
About NOVO NORDISK PHARMACEUTICALS A/S
NOVO NORDISK PHARMACEUTICALS A/S is a Danish company of the type Aktieselskab based in Bagsværd, founded in 1974. The company is registered under the industry Anden finansiel formidling i.a.n.. The company was previously named NOVO FARMAKA A/S. The management consists of Anders Rytter Mikkelsen. The board consists of Naja Eilers Barrisøe (chair), Linette Tangsgaard Nielsen and Thomas Rask Nielsen. The company is owned by NOVO NORDISK A/S. According to the 2025 annual report, the company had an average of 0 employees. In 2025, the company reported a gross profit of DKK -53,000 and a net result of DKK 2,074,000 compared with DKK 6,918,000 the year before. Equity in the 2025 report amounted to DKK 12,325,000.
